Dublin, March 31, 2022 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Market by Drug Type and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
The global idiopathic pulmonary fibrosis market was valued at $3,126.08 million in 2020, and is projected to reach $6,169.37 million by 2030, registering a CAGR of 7.0% from 2021 to 2030.
Idiopathic pulmonary fibrosis is a chronic lung disease or a condition in which the tissues in lungs become thick and stiff over time. As a result of thickening of lung tissues, brain, and other organs are unable receive optimum oxygen. This condition causes scar tissue (fibrosis) to build up in the lungs, which makes the lungs unable to transport oxygen into the bloodstream effectively. The disease usually affects people between the ages of 50 and 70. Idiopathic pulmonary fibrosis belongs to a group of conditions called interstitial lung diseases (also known as ILD), which describes lung diseases that involve inflammation or scarring in the lung.
The most common signs and symptoms of idiopathic pulmonary fibrosis are shortness of breath and a persistent dry, hacking cough. Many affected individuals also experience a loss of appetite and gradual weight loss. Some people with idiopathic pulmonary fibrosis develop widened and rounded tips of the fingers and toes (clubbing) resulting from a shortage of oxygen.
The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include rise in prevalence of fibrotic disease and increase in geriatric population. In addition, surge in demand for cost-effective drugs and introduction of advanced treatment options propel the market growth. However, unavailability of the proper treatment options of the disease restricts the market growth.
The global idiopathic pulmonary fibrosis market is segmented on the basis of type of drug, distribution channel and region. According to type of drug, the market is divided into pirfenidone and nintedanib. On the basis of distribution channel, the market is divided into hospital pharmacies, retail pharmacies and online providers. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA)
The major companies profiled in the report include AstraZeneca Plc, Biogen Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Inc., Mission Therapeutics., GNI Group Ltd, Galapagos NV, Biogen, Bristol-Myers Squibb Company., and Shiongi Co Ltd.
Key Benefits
- The study provides an in-depth analysis of the global idiopathic pulmonary fibrosis market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the products and end users of idiopathic pulmonary fibrosis used across the globe.
- Key market players and their strategies have been analysed to understand the competitive outlook of the market.
Key Topics Covered:
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top player positioning, 2020
3.4. Porter's five forces analysis
3.4.1. Bargaining power of suppliers
3.4.2. Bargaining power of buyers
3.4.3. Threat of new entrants
3.4.4. Threat of substitutes
3.4.5. Intensity of competitive rivalry
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.1.1. Increase in incidences of cancer across the globe
3.5.1.2. Surge in global geriatric population
3.5.1.3. Increase in cigarette smoking
3.5.2. Restraint
3.5.2.1. Lack of awareness & Proper treatment.
3.5.3. Opportunities
3.5.3.1. Increase in number of pipeline drugs
3.5.3.2. Growth opportunities in emerging markets
3.5.4. Impact analyses
3.6. COVID-19 impact analysis on market
3.7. Pipeline analyses
CHAPTER 4: IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Pirfenidone
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Nintedanib
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
CHAPTER 5: IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL
5.1. Overview
5.1.1. Market size and forecast, by distribution channel
5.2. Hospital- pharmacies
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Retail pharmacy
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Online Pharmacy
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6: IDIOPATHIC PULMONARY FIBROSIS MARKET, BY REGION
CHAPTER 7: COMPANY PROFILES
7.1. AstraZeneca Plc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. Bristol-Myers Squibb Company
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. Biogen,Inc
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. FibroGen, Inc
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. F. Hoffmann-La Roche AG
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. GNI Group Ltd.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Galapagos NV.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. Mission Therapeutics
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.10. Shionogi & Co Ltd
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
For more information about this report visit https://www.researchandmarkets.com/r/blfrr3
Attachment
